For citations:
Merseburger A.S., Agarwal N., Bhaumik A., Lefresne F., Karsh L.I., Pereira de Santana Gomes A.J., Juárez Soto Á., Given R.W., Brookman-May S.D., Mundle S.D., McCarthy S.A., Uemura H., Chowdhury S., Chi K.N., Bjartell A. Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study. Cancer Urology. 2024;20(1):79-93. (In Russ.) https://doi.org/10.17650/1726-9776-2024-20-1-79-93
Email this article 